Cullinan Oncology LLC (CGEM) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Cullinan Oncology LLC stock (CGEM) is currently trading at $13.64. Cullinan Oncology LLC PS ratio (Price-to-Sales) is 26.88. Analyst consensus price target for CGEM is $31.35. WallStSmart rates CGEM as Sell.
- CGEM PE ratio analysis and historical PE chart
- CGEM PS ratio (Price-to-Sales) history and trend
- CGEM intrinsic value — DCF, Graham Number, EPV models
- CGEM stock price prediction 2025 2026 2027 2028 2029 2030
- CGEM fair value vs current price
- CGEM insider transactions and insider buying
- Is CGEM undervalued or overvalued?
- Cullinan Oncology LLC financial analysis — revenue, earnings, cash flow
- CGEM Piotroski F-Score and Altman Z-Score
- CGEM analyst price target and Smart Rating
Cullinan Oncology LLC
📊 No data available
Try selecting a different time range
Smart Analysis
Cullinan Oncology LLC (CGEM) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around return on equity and price/sales. Significant fundamental concerns warrant caution or avoidance.
Cullinan Oncology LLC (CGEM) Key Strengths (2)
105.48% of shares held by major funds and institutions
Trading at 1.89x book value, attractively priced
Supporting Valuation Data
Cullinan Oncology LLC (CGEM) Areas to Watch (3)
Company is destroying shareholder value
Very expensive at 26.9x annual revenue
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Cullinan Oncology LLC (CGEM) Detailed Analysis Report
Overall Assessment
This company scores 24/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 2 register as strengths (avg 9.0/10) while 3 fall into concern territory (avg 2.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Book. Valuation metrics including Price/Book (1.89) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Market Cap. Some valuation metrics including Price/Sales (26.88) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -44.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -44.00% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CGEM Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CGEM's Price-to-Sales ratio of 26.88x trades 41% below its historical average of 45.8x (12th percentile). The current valuation is 79% below its historical high of 126.05x set in Feb 2021, and 45% above its historical low of 18.59x in Sep 2025.
WallStSmart Analysis Synopsis
Data-driven financial summary for Cullinan Oncology LLC (CGEM) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Cullinan Oncology LLC operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Free cash flow is -38M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Cullinan Oncology LLC.
Bottom Line
Cullinan Oncology LLC offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Cullinan Oncology LLC(CGEM)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company is headquartered in Cambridge, Massachusetts.